M Ventures

The strategic corporate venture capital arm of Merck KGaA, investing in Biotechnology and Technology.

Corporate VC Active Darmstadt, Germany Est. 2009
Visit website ↗ LinkedIn
Last updated 2026-07-20
Portfolio
5
in our dataset
Rounds participated
12
Rounds led
0
Rounds' value
$32.6M
total disclosed, rounds participated
Stages
Seed, Pre-Seed

About

M Ventures is the strategic corporate venture capital fund of Merck KGaA, Darmstadt, Germany. It invests globally in innovative technologies and products with the potential to significantly impact Merck's core business areas across Healthcare, Life Sciences, Electronics, Frontier Tech, and Sustainability. M Ventures operates with a dual mandate of strategic and financial returns, taking an active role in its portfolio companies and supporting entrepreneurs from company creation to commercial success. They have a strong presence in the Israeli ecosystem, including an Israel Bioincubator in Yavne.

Portfolio · 5

Sentaur Biosciences
Pioneering Precision Therapeutics for Senescence Driven Diseases
3 rounds Latest: 2023-07
Metabomed
Target-inhibiting Anticancer Drugs
4 rounds $30.5M committed Latest: 2022-04
Pantheon Bioscience
Platform of Bacterial Defense Mechanism
2 rounds $2.1M committed Latest: 2019-06
ARTSaVIT
Cancer Apoptosis Technology
2 rounds Latest: 2018-03
ChanBio
Biopharmaceuticals for Treatment of Multiple Sclerosis
1 round Latest: 2013-11

Investment activity

2 portfolio exits on record.

Portfolio by sector

Health Tech & Life Sciences11
Industrial Technologies4
Fintech & Insurtech1

Q&A

What is M Ventures' primary investment focus and strategy?
M Ventures is the strategic corporate venture arm of Merck KGaA of Darmstadt, Germany. It operates as an evergreen fund, focusing on Biotechnology and Technology in alignment with Merck's strategic interests in Healthcare, Life Sciences, Electronics, Frontier Tech, and Sustainability.
What is M Ventures' geographic focus for investments?
M Ventures is active in the Israeli ecosystem, investing in Israeli companies within its fields of interest.
Does M Ventures provide any additional support to its portfolio companies beyond financing?
Yes, M Ventures holds an incubator facility in Israel, offering seed financing and access to dedicated laboratories within Merck's Israel-based biopharma R&D center for its portfolio companies.
Can you name a recent exit for M Ventures?
In February 2023, M Ventures saw an exit with Immunorizon, which was acquired by Purple Biotech for $100M.
What are M Ventures' typical investment stages?
M Ventures primarily invests in Seed and Pre-Seed stage companies.
Which sectors does M Ventures concentrate its investments in?
M Ventures shows a strong concentration in Health Tech & Life Sciences, with 11 portfolio companies, and Industrial Technologies, with 4 portfolio companies.
Who leads M Ventures' Israeli Bio-Incubator?
Noga Yerushalmi serves as the Head of M Ventures' Israeli Bio-Incubator.
Can you name a notable recent investment by M Ventures?
M Ventures participated in a Seed round for lizo.AI in April 2024, which raised $4M for its AI-based operating system for Real Estate Investments.
What is one of M Ventures' larger portfolio companies by funding raised?
Wiliot, a company developing battery-free Bluetooth tags, has raised $344M and is a portfolio company of M Ventures.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)